A total of 13% of cancers that were HER2 (+) in primary cancer were found to be HER2 (−) in metastatic lesion, whereas 5% to be negative in the primary tumor were positive in metastatic specimen in a meta-analysis [16]. This evidence concerns the gene ERBB2 and cancer.